文献速递肿瘤 PET/CT

比较[68Ga]Ga-DOTA-FAPI-04与[18F]FDG PET/CT在多种癌症患者原发灶和转移灶诊断中的价值

Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-03-28

本研究纳入75例多种类型癌症患者,同期行[68Ga]Ga-DOTA-FAPI-04与[18F]FDG PET/CT检查,用于初诊评估或复发检测。结果显示[68Ga]Ga-DOTA-FAPI-04 PET/CT对原发肿瘤检出率(98.2% vs. 82.1%,P=0.021)及淋巴结(86.4% vs. 45.5%,P=0.004)和骨及内脏转移(83.8% vs. 59.5%,P=0.004)的敏感性均优于[18F]FDG PET/CT。

要点

  • [68Ga]Ga-DOTA-FAPI-04 PET/CT原发肿瘤检出率98.2%,高于[18F]FDG PET/CT的82.1%(P=0.021)。
  • 淋巴结转移敏感性86.4% vs. 45.5%(P=0.004),骨及内脏转移83.8% vs. 59.5%(P=0.004),均更优。
  • 在识别肝转移、腹膜癌病和脑肿瘤方面尤其有优势。

核心结论

  • [68Ga]Ga-DOTA-FAPI-04 PET/CT对多种癌症原发灶和转移灶的诊断效能优于[18F]FDG PET/CT,尤其在识别肝转移、腹膜癌病和脑肿瘤方面。

研究设计与样本

  • 共纳入75例多种类型癌症患者(47例男性,28例女性;中位年龄61.5岁,年龄范围32-85岁)。
  • 54例含12种不同肿瘤类型的患者行配对[68Ga]Ga-DOTA-FAPI-04与[18F]FDG PET/CT用于初诊评估,另21例行配对扫描用于复发检测。
  • 肿瘤摄取以最大标准摄取值(SUVmax)量化,计算并比较两种PET/CT的敏感性、特异性、阳性预测值、阴性预测值和准确性。

主要发现

  • [68Ga]Ga-DOTA-FAPI-04 PET/CT能清晰识别12种恶性肿瘤,肿瘤-背景对比良好,原发肿瘤检出率高于[18F]FDG PET/CT(98.2% vs. 82.1%,P=0.021)。
  • [68Ga]Ga-DOTA-FAPI-04 PET/CT检测淋巴结转移的敏感性优于[18F]FDG PET/CT(86.4% vs. 45.5%,P=0.004)。
  • [68Ga]Ga-DOTA-FAPI-04 PET/CT检测骨及内脏转移的敏感性优于[18F]FDG PET/CT(83.8% vs. 59.5%,P=0.004)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We evaluated the potential usefulness of [68Ga]Ga-DOTA-FAPI-04 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer, compared with [18F] FDG PET/CT. METHODS: A total of 75 patients with various types of cancer underwent contemporaneous [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT either for an initial assessment or for recurrence detection. Tumour uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of [18F] FDG and [68Ga]Ga-DOTA-FAPI-04 PET/CT were calculated and compared to evaluate the diagnostic efficacy. RESULTS: The study cohort consisted of 75 patients (47 males and 28 females; median age, 61.5 years; age range, 32-85 years). Fifty-four patients with 12 different tumour entities underwent paired [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for initial assessment, while the other 21 patients underwent paired scans for recurrence detection. [68Ga]Ga-DOTA-FAPI-04 PET/CT was able to clearly identify 12 types of malignant tumours with favourable tumour-to-background contrast, which resulted in a higher detection rate of primary tumours than did [18F] FDG PET/CT (98.2% vs. 82.1%, P = 0.021). Meanwhile, [68Ga]Ga-DOTA-FAPI-04 PET/CT showed a better sensitivity than [18F] FDG PET/CT in the detection of lymph nodes (86.4% vs. 45.5%, P = 0.004) and bone and visceral metastases (83.8% vs. 59.5%, P = 0.004). CONCLUSION: [68Ga]Ga-DOTA-FAPI-04 PET/CT showed a superior diagnostic efficacy than [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer, especially in identifying liver metastases, peritoneal carcinomatosis, and brain tumours.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Chen H, Pang Y, Wu J, et al. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020. PMID: 32222810. doi:10.1007/s00259-020-04769-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。